On May 14, 2025, the heart of Vienna became the stage for Onco:Innovate 2025, a premier European gathering that united healthcare innovators, researchers, policy makers, and digital health experts to shape the future of cancer care. Among the standout participants was Womeno, our Bulgarian digital health startup that is redefining post-treatment care for women who face early menopause as a result of cancer therapy.
During the Startup Spotlight session, Kalina Milanova, founder of Womeno, introduced the platform to the international audience. Alongside her, Maria Krastanova shared her deeply personal story of entering early menopause following breast cancer treatment, powerfully illustrating the human impact behind the innovation Womeno is driving. Their presentation highlighted how the platform directly addresses a crucial gap in women’s health—treatment-induced menopause—by offering expert-driven, personalized support. Every year, over 25 million women globally enter menopause, and 94% of them lack access to essential care. For many cancer survivors, chemotherapy and related treatments can trigger early menopause, compounding their physical and emotional challenges. Womeno aims to be a lifeline in this critical transition, using technology to offer compassionate, tailored solutions.
Womeno’s digital platform integrates several advanced features to serve both individuals and organizations. It offers a B2B Customized Meno Test, enabling companies and healthcare providers to better support female employees and patients. Through anonymized data analytics, the platform helps identify trends and optimize care pathways. Educational workshops, webinars, and employer branding solutions aim to raise awareness and foster supportive environments in the workplace.
On the B2C side, Womeno provides a robust mobile app where users can track daily symptoms, receive detailed health reports, access telemedicine services, and benefit from enhanced medical check-ups and video tutorials by experts. The app is designed to offer not just care, but convenience and empowerment. Women can also share their reports with doctors, receive health insights based on analytics, and access exclusive perks and offers. Looking ahead, the Womeno team is planning to launch “Dr. Womeno,” an AI-based companion that will further personalize the care experience.
At the conference, the team also presented their expert network and shared the startup’s development timeline, underscoring the strong foundation and structured growth strategy behind their mission.
Womeno’s impact resonated strongly with Onco:Innovate organizers and participants. Although the event wasn’t framed as a competition, Womeno was selected to represent the cohort at the Health Tech Forward (HTF) conference in Barcelona this December. According to the organizers, Womeno was chosen because of its sharp focus on digital health, its clear relevance to women’s health, and its potential for broader European impact. HTF organizers noted that Womeno is not only invited to attend but is also eligible to participate in their Women’s Health pitching track, offering the startup a platform to share its vision on stage before a global health tech audience.
This recognition marks an exciting new chapter for Womeno, validating the startup’s mission and opening doors to new partnerships, investment, and visibility across the health innovation landscape. As digital health continues to transform how we prevent, manage, and recover from disease, Womeno is ensuring that women’s needs—particularly during the often-overlooked menopausal transition—are no longer sidelined.
Onco:Innovate 2025 was not just a celebration of cutting-edge science and technology; it was a call to action for inclusive, patient-centered innovation. For Womeno, it was both a milestone and a launchpad toward reshaping post-cancer care for millions of women worldwide.
Stay tuned as the Womeno journey continues—next stop, Barcelona.
